OBI Pharma, Inc.
Industry Group: Pharmaceuticals
Country/Region: Taiwan
Identifier: ROCO:4174
OBI Pharma Inc is part of the healthcare sector. The company and its subsidiaries are engaged in new drug research. Its focus is on the unmet medical need in challenging diseases throughout the world, such as cancer. OBI strives to improve health and the quality of life through cost-effective therapeutics. The group has four reportable segments, which are the anti-cancer new drug segment, bispecific monoclonal antibody new drug segment, botulinum toxin new drug segment, and CDMO segment.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 176 out of 850
Universe
Global Universe 7186 out of 15081
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| Emergent BioSolutions, Inc. |
21.7
Medium
|
116 out of 850 |
| OBI Pharma, Inc. |
24.4
Medium
|
176 out of 850 |
| Xeris Biopharma Holdings, Inc. |
27.4
Medium
|
333 out of 850 |
| Aura Biosciences, Inc. |
27.4
Medium
|
336 out of 850 |
| UroGen Pharma Ltd. |
29.8
Medium
|
480 out of 850 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.